Dr. Sainan Hu 胡赛男
Chief Physician
Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis, chemotherapy, molecular targeted therapy, and comprehensive treatment for common malignant solid tumors, with a focus on individualized care for breast cancer, gastrointestinal tumors, and lung cancer.
Dr. Hu graduated from the Department of Clinical Medicine at Nanjing Medical University and has worked in medical oncology for over 20 years. Dr. Hu participates in multiple international and domestic multicenter clinical studies and is skilled in diagnosing and treating common malignant solid tumors, particularly breast cancer.
Professional roles
- Member, Youth Committee of the Clinical Chemotherapy Professional Committee, China Anti-Cancer Association
- Member, Tumor Drug Genomics Professional Committee, Chinese Society of Biotechnology
- Member, Breast Cancer Group, Oncology Chemotherapy and Biotherapy Professional Committee, Jiangsu Medical Association
- Breast Cancer Quality Control Expert, Jiangsu Provincial Oncology Professional Quality Control Center
Name order: in Chinese the family name comes first (Hu Sainan). Papers usually list the name as Sainan Hu or Hu S.
Selected publications
9 papers on PubMed matched by name and affiliation; 3 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cancer Cell Int, 2021 (senior author): Retraction Note to: Inhibition of ZEB1-AS1 confers cisplatin sensitivity in breast cancer by promoting microRNA-129-5p-dependent ZEB1 downregulation. PubMed 33430826
- Cancer Cell Int, 2020 (senior author): Inhibition of ZEB1-AS1 confers cisplatin sensitivity in breast cancer by promoting microRNA-129-5p-dependent ZEB1 downregulation. PubMed 32210737
- J Cell Physiol, 2019 (senior author): MicroRNA-590-5p functions as a tumor suppressor in breast cancer conferring inhibitory effects on cell migration, invasion, and epithelial-mesenchymal transition by downregulating the Wnt-β-catenin signaling pathway. PubMed 30191949
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion